M C Riddle
Affiliation: Oregon Health and Science University
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)Matthew C Riddle
Corresponding author Matthew C Riddle
Diabetes Care 36:2489-96. 2013....
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)Matthew C Riddle
Corresponding author Matthew C Riddle
Diabetes Care 36:2497-503. 2013....
- Reevaluating goals of insulin therapy: perspectives from large clinical trialsMatthew C Riddle
Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Mailcode L345, Portland, OR 97239, USA
Endocrinol Metab Clin North Am 41:41-56. 2012..This article surveys recent epidemiologic studies and interventional trials, examines the current understanding of the natural history of type 2 diabetes, and proposes new goals and tactics for optimizing insulin therapy...
- Making the transition from oral to insulin therapyMatthew C Riddle
Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97201, USA
Am J Med 118:14S-20S. 2005..Future studies should consider not only the ability of regimens to reach hemoglobin A(1c) targets but also the burden of adverse effects accompanying this effort with a given method...
- Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinationsMatthew C Riddle
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, 3181 SW Sam Jackson Park Drive, Portland, OR 97239 3098, USA
Endocrinol Metab Clin North Am 34:77-98. 2005..For now, systematic application of the scheme (see Fig. 4) should improve the success of treatment greatly from its currently disappointing level...
- Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessaryMatthew C Riddle
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University L 345, Portland, Oregon 97239 3098, USA
J Clin Endocrinol Metab 93:372-4. 2008
- Combined therapy with insulin plus oral agents: is there any advantage? An argument in favorMatthew C Riddle
Section of Diabetes L 345, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201, USA
Diabetes Care 31:S125-30. 2008
- Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trialMatthew C Riddle
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
Diabetes Care 33:983-90. 2010..As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality...
- The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsMatthew C Riddle
Oregon Health and Science University, Portland, Oregon 97201, USA
Diabetes Care 26:3080-6. 2003..To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c)...
- The underuse of insulin therapy in North AmericaMatthew C Riddle
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University, Portland, OR 97201, USA
Diabetes Metab Res Rev 18:S42-9. 2002..Several new treatment options are discussed...
- Pramlintide: an agent for glycemic control plus weight control?Matthew C Riddle
Department of Medicine, Oregon Health and Science University, Portland 97201, USA
Diabetes Technol Ther 4:63-5. 2002
- Combining sulfonylureas and other oral agentsM Riddle
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University, Portland, Oregon 97201, USA
Am J Med 108:15S-22S. 2000..Later in the course of the disease, the use of combinations of oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients...
- Timely initiation of basal insulinMatthew C Riddle
Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
Am J Med 116:3S-9S. 2004..To maintain the recommended <7% HbA(1c) target level of control, treatments that target postprandial hyperglycemia will have to be added to basal insulin later on, as endogenous insulin continues to decline...
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trialFaramarz Ismail-Beigi
Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
Lancet 376:419-30. 2010..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
- The Treat-to-Target Trial and related studiesMatthew C Riddle
Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Sciences University, Portland, USA
Endocr Pract 12:71-9. 2006..To describe the rationale for, and the findings of, the Treat-to-Target Trial and to compare its results with those of two subsequent studies based on the same concepts...
- Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routineM C Riddle
Department of Medicine, Oregon Health Sciences University, Portland, USA
Horm Metab Res 28:430-3. 1996..The available evidence suggests this form of combined therapy is suitable for routine use...
- Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metforminMatthew C Riddle
Oregon Health and Sciences University, Portland, OR, USA
Diabetes Metab Res Rev 22:483-91. 2006..This analysis examines the effects of 82 weeks of exenatide treatment for participants in these earlier 30-week trials...
- Current oral agents for type 2 diabetes. Many options, but which to choose when?Andrew J Ahmann
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University School of Medicine, 3181 SW Sam Jackson Park Rd, OP05, Portland, OR 97201 3098, USA
Postgrad Med 111:32-4, 37-40, 43-6. 2002..In this article, Drs Ahmann and Riddle provide an overview of the oral agents now available for the treatment of diabetes and discuss the clinical factors that help determine when to use which medication and what outcome to expect...
- Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1Matthew C Riddle
Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
Diabetes Care 29:435-49. 2006
- Timely addition of insulin to oral therapy for type 2 diabetesMatthew C Riddle
Diabetes Care 25:395-6. 2002
- Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?Matthew C Riddle
J Clin Endocrinol Metab 88:528-30. 2003
- What to do when two oral agents fail to control type 2 diabetes--a matter of opinion or a matter of fact?Andrew J Ahmann
Am J Med 116:276-8. 2004
- Type 2 diabetes: the role of basal insulin therapyDerek LeRoith
J Fam Pract 53:215-22. 2004
- Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)Hertzel Gerstein
Am Heart J 155:26-32, 32.e1-6. 2008..Thus, targeting normal fasting glucose levels with insulin may reduce CV events. Previous studies suggest that omega-3 fatty acid supplements may reduce CV death; however, their effect in high-risk dysglycemic individuals is not known...
- Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetesHans U Janka
Zentralkrankenhaus, Bremen Nord, II Medizinische Abteilung, Hammersbecker Str 228, 28755 Bremen, Germany
Diabetes Care 28:254-9. 2005..To compare the efficacy and safety of adding once-daily basal insulin versus switching to twice-daily premixed insulin in type 2 diabetic patients insufficiently controlled by oral antidiabetic agents (OADs)...
- Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitusPeter Mullins
Department of Statistics, University of Auckland, Auckland, New Zealand
Clin Ther 29:1607-19. 2007..The model was then used to compare rates of hypoglycemia associated with use of these insulins...
- Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialHertzel C Gerstein
Department of Medicine and the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
Am J Cardiol 99:34i-43i. 2007..It will also provide information on how to safely approach near-normal levels of glucose control in clinical practice and evidence to support future clinical guidelines for diabetes management in older adults...
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDavid M Kendall
International Diabetes Center and University of Minnesota, Minmneapolis, MN, USA
Diabetes Care 28:1083-91. 2005..This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy...
- ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendationsHarold E Lebovitz
Endocr Pract 12:6-12. 2006